[Signal Transduction and Targeted Therapy] The authors identified SUMOylation as a specific, druggable regulator of RAC1-driven breast cancer metastasis using genetic mouse models and patient-derived organoids.

[Advanced Science] Researchers uncovered a cancer-associated fibroblast-exosomal circFAD104 axis that reprograms glucose metabolism to drive TNBC progression.

[Advanced Science] Scientists identified an enhancer-driven transcriptional program that promotes breast cancer metastasis under nutrient deprivation.

[Cell Reports Medicine] Investigators identified non-canonical functions of the extracellular matrix remodeler, lysyl oxidase (LOX), and showed that inhibiting LOX generates targetable vulnerability to ferroptosis in TNBC.

[Science Advances] The authors showed that methylscape, a cancer-specific DNA methylation landscape, can be leveraged to monitor cancer progression.

[EMBO Journal] Investigators combined CRISPRi-mediated ZSWIM8 depletion, miRNA-seq, and AGO2-eCLIP to define the target-directed microRNA degradation landscape across breast cancer subtypes.

[Cancer Letters] Researchers developed a new preclinical model of HER2+ leptomeningeal metastasis where Trastuzumab deruxtecan demonstrated potent, dose-dependent antitumor activity.

[Cell Death Discovery] The authors found that concurrent upregulation of p62 and basal level of autophagy were the driving forces in acquiring radioresistance in triple negative breast cancer cells.

[Journal of Ethnopharmacology] Scientists showed the Xingxiao Pill inhibits 4T1 breast cancer cell proliferation and promotes apoptosis in vitro and in vivo, possibly by inhibiting the ErbB3/PI3K/AKT/mTOR signaling pathway, regulating amino acid metabolism, and promoting caspase-mediated endogenous apoptosis.

[Journal of Hematology & Oncology] The authors review current and emerging therapeutic strategies for TNBC through a three-layer framework: tumor-cell-intrinsic vulnerabilities, the local immune and stromal microenvironment, and host-level systemic modifiers.

[Molecular Biology Reports] Scientists try to dissect the complex landscape related to changes in gene expression control dynamics in breast cancer with a thorough examination of the tumor microenvironment.

[AstraZeneca] Enhertu^®, trastuzumab deruxtecan, in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.